The present evidence of CCL21-CCR7 signaling role in GBM progression, through promoting tumor cell proliferation/survival and the tumor-supportive behavior of TAMs, therefore indicate CCL21-CCR7 blocking drugs as new opportunities to normalize the TME, reduce resistance to chemotherapy treatment, and thus improve anti-GBM chemotherapy. Here, CCR7 is linked to neoplasm.